pazopanib has been researched along with Esophageal-Neoplasms* in 2 studies
2 other study(ies) available for pazopanib and Esophageal-Neoplasms
| Article | Year |
|---|---|
Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged, 80 and over; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophagus; Fatal Outcome; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrimidines; Stomach; Stomach Neoplasms; Sulfonamides; Treatment Outcome | 2019 |
Renal cell cancer metastases to esophagus and stomach successfully treated with radiotherapy and pazopanib.
Renal cell cancer has been rarely reported as a cause of gastric or esophageal metastases. They usually present with gastrointestinal bleeding and most cases have been managed surgically or endoscopically. We report the case of a 38-year-old man with a 4-year history of metastatic renal cell carcinoma admitted to the emergency room with melena and anemia. At endoscopy, three esophageal polypoid lesions (middle and distal thirds) and a 7 cm mass in the gastric fundus were identified. Biopsy revealed esophageal mucosa infiltrated by renal cell carcinoma. Radiotherapy was administered (30 Gy in 10 fractions), followed by pazopanib, with excellent tolerance and without new bleeding episodes. Computed tomography scan showed complete disappearance of the esophageal and fundic lesions at 3 months follow-up. Twenty-four months after being initiated on pazopanib, there is no radiological evidence of disease. This is the first reported case showing complete remission of gastric and esophageal metastases after treatment with radiotherapy and pazopanib. Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Esophageal Neoplasms; Gastric Fundus; Humans; Indazoles; Kidney Neoplasms; Male; Pyrimidines; Stomach Neoplasms; Sulfonamides | 2015 |